-
Mashup Score: 0Molecular Classification of Cancers of Unknown Primary Expands and Refines Treatment Options - Tempus - 1 year(s) ago
Background: Patients with cancer of unknown primary (CUP) have a poor prognosis due to delays in diagnostic workup and empirically-selected platinum-based regimens that may not be the most active first line for the primary disease. The Tempus Tumor Origin (TO) test is a machine learning classifier that uses RNA-Seq data to identify the most likely … Continued
Source: TempusCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0The genomic landscape of small cell lung cancer in never smoking patients | OncologyPRO - 1 year(s) ago
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The genomic landscape of small cell lung cancer in never smoking patients [Sep 12, 2022] Oh et al. #ESMO22 Oral Discussion (1529MO) https://t.co/Mo8i55iK4Y #PrecisionMedicine #lcsm @UCLA @dgsomucla @TempusLabs
-
-
Mashup Score: 0
OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,
Source: oncologypro.esmo.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
BRAF mutations and fusions in a real-world cohort of non-small cell lung cancer patients [Sep 12, 2022] Niu et al. #ESMO22 Abstract 1107P https://t.co/l8uUlYKK6P #PrecisionMedicine #lcsm @Bannermdandersn @TempusLabs
-
-
Mashup Score: 3Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer - 1 year(s) ago
The use of an individualized starting dose of niraparib led to a trend toward improved overall survival as maintenance therapy vs placebo in Chinese patients with platinum-sensitive, recurrent ovarian cancer regardless of germline BRCA mutation status, according to data from the phase 3 NORA trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Individualized Maintenance Niraparib Dosing Confers Favorable OS in Recurrent Ovarian Cancer #ovca @myESMO #ESMO22 https://t.co/KFRrHTd8ad
-
-
Mashup Score: 0
Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at the 2022 European Society for Medical Oncology Congress.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Susana Banerjee, MBBS, PhD, discusses the updated results of the MEDIOLA trial of patients with ovarian cancer presented at #ESMO22. #GYNCSM | @royalmarsdenNHS https://t.co/vxsqyj1GOg
-
-
Mashup Score: 3
Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an…
Source: UroTodayCategories: Hem/Oncs, Latest HeadlinesTweet-
My discussion of emerging therapeutic landscape for metastatic #bladdercancer #urothelialcarcinoma with @CaPsurvivorship #esmo22 - 1L cisplatin-ineligible ->EV-pembro, adjuvant nivolumab https://t.co/LeDqJUFhTR @urotoday
-
-
Mashup Score: 2ACLC & ESMO Asia Highlights | IASLC - 1 year(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu invited guests to discuss the IASLC Asian Conference on Lung Cancer (ACLC) held in Japan and the …
Source: IASLCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In this episode, @StephenVLiu discusses the #ACLC22 & #ESMO22 meetings w/guests Dr. James Yang (National Taiwan University Hospital), @reungwetwattana (@Ramathibodi & @MahidolU), & Dr. Takashi Setothor (National Kyushu Cancer Center). Listen: https://t.co/KUq321rUo7 #LCSM https://t.co/65CugQlknm
-
-
Mashup Score: 0Sintilimab Plus Anlotinib Improves Responses, PFS Vs Chemotherapy in Untreated NSCLC - 1 year(s) ago
The combination of sintilimab and anlotinib elicited improved responses and progression-free survival compared with chemotherapy in previously untreated patients with metastatic non–small cell lung cancer.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Sintilimab Plus Anlotinib Improves Responses, PFS Vs Chemotherapy in Untreated NSCLC @myESMO #ESMO22 #lcsm #oncology https://t.co/gxGipVDsjR
-
-
Mashup Score: 0NEOpredict-Lung Data Support the Addition of Relatlimab to Preoperative Nivolumab in Resectable NSCLC - 1 year(s) ago
Evan J. Lipson, MD, expands on key takeaways from the NEOpredict-Lung trial, the additional benefit that PICIT may offer to patients who progress on other immunotherapies, and the effect that both NEOpredict-Lung and RELATIVITY-047 have on the role of immunotherapy in the lung and melanoma treatment paradigms.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEOpredict-Lung Data Support the Addition of Relatlimab to Preoperative Nivolumab in Resectable NSCLC @evanlipson @hopkinskimmel #lcsm #ESMO22 https://t.co/IGRnrXQT8C
-
-
Mashup Score: 3Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC - The ASCO Post - 1 year(s) ago
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved regardless of prior adjuvant chemotherapy or disease stage, according to updated findings from the phase…
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC https://t.co/SW7LumhpGZ #LCSM #lungcancer #oncology #ESMO22
-
Molecular classification of cancers of unknown primary expands and refines treatment options [Sep 11, 2022] George et al. #ESMO22 Poster 923P https://t.co/Ha5SUb88Zl & https://t.co/6vxGpOv5PJ #PrecisionMedicine #CUPsm @TempusLabs